2 Information about risankizumab

Marketing authorisation indication


Risankizumab (Skyrizi, AbbVie) is indicated for 'the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biological therapy, or if such therapies are not advisable'.



The company has stated that the list prices of the 600‑mg concentrate for solution for infusion (induction treatment) and the on-body device with 360‑mg solution for injection (maintenance treatment) are confidential until they are available, and cannot be reported here.


The company has a commercial arrangement. This makes risankizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.